Table C12Base case drug efficacy inputs

Weighted mean difference % change in HbA1cChange in TC:HDL*Change in SBP
Biphasic analogue vs human insulin−0.0200
Glargine vs human insulin0.0400
Glargine vs biphasic analogue0.4300
Exenatide vs glargine0.08−0.12−3.58
Exenatide vs biphasic analogue−0.090.1−6.22
Rosiglitazone vs glargine0.150.420
Pioglitazone vs rosiglitazone−0.1−1.080
*

Calculations for the change in TC:HDL are shown in tables 52 to 54 at the end of this appendix. Conversion rate of mg/dl to mmol/l=0.0259.410

From: Appendix C, Health economic analysis of third-line therapy with insulins, glitazones or exenatide in Type 2 diabetes

Cover of Type 2 Diabetes
Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update).
NICE Clinical Guidelines, No. 66.
National Collaborating Centre for Chronic Conditions (UK).
Copyright © 2008, Royal College of Physicians of London.

All rights reserved. No part of this publication may be reproduced in any form (including photocopying or storing it in any medium by electronic means and whether or not transiently or incidentally to some other use of this publication) without the written permission of the copyright owner. Applications for the copyright owner’s written permission to reproduce any part of this publication should be addressed to the publisher.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.